Li Kongwei, Li Kaiyue, He Yuan, Liang Shan, Shui Xiaorong, Lei Wei
Guangdong Provincial Engineering Technology Research Center for Molecular Diagnosis and Innovative Drugs Translation of Cardiopulmonary Vascular Diseases, University Joint Laboratory of Guangdong Province and Macao Region on Molecular Targets and Intervention of Cardiovascular Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China; Cardiovascular Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China; Department of Precision Laboratory, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Guangdong Provincial Engineering Technology Research Center for Molecular Diagnosis and Innovative Drugs Translation of Cardiopulmonary Vascular Diseases, University Joint Laboratory of Guangdong Province and Macao Region on Molecular Targets and Intervention of Cardiovascular Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China; Department of Precision Laboratory, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Biochem Pharmacol. 2023 Oct;216:115744. doi: 10.1016/j.bcp.2023.115744. Epub 2023 Aug 12.
Cardiovascular disease is the leading cause of death worldwide, and atherosclerosis is a major contributor to this etiology. The ligand-activated transcription factor, known as the aryl hydrocarbon receptor (AhR), plays an essential role in the interactions between genes and the environment. In a number of human diseases, including atherosclerosis, the AhR signaling pathway has recently been shown to be aberrantly expressed and activated. It's reported that AhR can regulate the immuno-inflammatory response and metabolism pathways in atherosclerosis, potentially serving as a bridge that links these processes. In this review, we highlight the involvement of AhR in atherosclerosis. From the literature, we conclude that AhR is a potential target for controlling atherosclerosis through precise interventions.
心血管疾病是全球主要的死亡原因，而动脉粥样硬化是这一病因的主要促成因素。配体激活的转录因子，即芳烃受体（AhR），在基因与环境的相互作用中起着至关重要的作用。在包括动脉粥样硬化在内的许多人类疾病中，最近已表明AhR信号通路存在异常表达和激活。据报道，AhR可调节动脉粥样硬化中的免疫炎症反应和代谢途径，可能充当连接这些过程的桥梁。在本综述中，我们重点介绍了AhR在动脉粥样硬化中的作用。从文献中，我们得出结论，AhR是通过精确干预控制动脉粥样硬化的潜在靶点。
